Publication:
Protective effect of cysteinyl leukotriene receptor antagonist montelukast in bleomycin-induced pulmonary fibrosis

Simple item page
dc.contributor.authorCEYHAN, BERRİN
dc.contributor.authorsTopaloglu, Nurhayat; Yildizeli, Sehnaz Olgun; Sener, Goksel; Lacin, Tunc; Sehirli, Ozer; Bozkurtlar, Emine; Celikel, Cigdem; Ceyhan, Berrin
dc.date.accessioned2022-04-25T00:11:17Z
dc.date.available2022-04-25T00:11:17Z
dc.date.issued2018
dc.description.abstractBackground: This study aims to investigate the early- and late-term effects of pharmacological inhibition of cysteinyl leukotriene activity by using montelukast in bleomycin-induced inflammatory and oxidative lung injury in an animal model. Methods: The study included 48 male Wistar albino rats (weighing 250 g to 300 g). Rats were administered intratracheal bleomycin or saline and assigned into groups to receive montelukast or saline. Bronchoalveolar lavage fluid and lung tissue samples were collected four and 15 days after bleomycin administration. Results: Bleomycin resulted in significant increases in tumor necrosis factor-alpha levels (4.0 +/- 1.4 pg/mL in controls vs. 44.1 +/- 14.5 pg/mL in early-term vs. 30.3 +/- 5.7 pg/mL in late-term, p<0.001 and p<0.001, respectively), transforming growth factor beta 1 levels (28.6 +/- 6.6 pg/mL vs. 82.3 +/- 14.1 pg/mL in early-term vs. 60.1 +/- 2.9 pg/mL in late-term, p<0.001 and p<0.001, respectively), and fibrosis score (1.85 +/- 0.89 in early-term vs. 5.60 +/- 1.14 in late-term, p<0.001 and p<0.01, respectively). In bleomycin exposed rats, collagen content increased only in the late-term (15.3 +/- 3.0 mu g/mg in controls vs. 29.6 +/- 9.1 mu g/mg in late-term, p<0.001). Montelukast treatment reversed all these biochemical indices as well as histopathological alterations induced by bleomycin. Conclusion: Montelukast attenuates bleomycin-induced inflammatory and oxidative lung injury and prevents lung collagen deposition and fibrotic response. Thus, cysteinyl leukotriene receptor antagonists might be regarded as new therapeutic agents for idiopathic pulmonary fibrosis.
dc.identifier.doi10.5606/tgkdc.dergisi.2019.15149
dc.identifier.issn1301-5680
dc.identifier.pubmed32082801
dc.identifier.urihttps://hdl.handle.net/11424/263877
dc.identifier.wosWOS:000450917400010
dc.languageeng
dc.publisherBAYCINAR MEDICAL PUBL-BAYCINAR TIBBI YAYINCILIK
dc.relation.ispartofTURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBleomycin
dc.subjectcollagen
dc.subjectglutathione
dc.subjectinterstitial lung disease
dc.subjectmalondialdehyde
dc.subjectmyeloperoxidase
dc.subjecttransforming growth factor beta 1
dc.subjecttumor necrosis factor-alpha
dc.subjectGROWTH-FACTOR-BETA
dc.subjectNECROSIS-FACTOR-ALPHA
dc.subjectMOUSE MODEL
dc.subjectMECHANISMS
dc.subjectPATHOGENESIS
dc.subjectCOLLAGEN
dc.subjectINJURY
dc.subjectCELLS
dc.subjectPROLIFERATION
dc.subjectEXPRESSION
dc.titleProtective effect of cysteinyl leukotriene receptor antagonist montelukast in bleomycin-induced pulmonary fibrosis
dc.typearticle
dspace.entity.typePublication
local.avesis.id7eb02d3b-062f-4625-954b-a16e1ae78e05
local.import.packageSS39
local.indexed.atWOS
local.journal.numberofpages10
local.journal.quartileQ4
oaire.citation.endPage597
oaire.citation.issue4
oaire.citation.startPage588
oaire.citation.titleTURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
oaire.citation.volume26
relation.isAuthorOfPublication14f2d015-b03a-45e7-bb38-e82572308bca
relation.isAuthorOfPublication.latestForDiscovery14f2d015-b03a-45e7-bb38-e82572308bca

Files

Collections

Research Outputs